|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Paraneoplastic Neurological Syndromes Evaluation with Recombx®, Initial Assessment
Test Code92423
CPT Codes
83520 (x8)<br /> Restricted Client Code
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Preferred Specimen
2 mL serum
Minimum Volume
0.5 mL
Other Acceptable Specimens
CSF collected in a sterile leak-proof container
Instructions
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Serum must be separated from cells within 48 hours of collection.
Serum must be separated from cells within 48 hours of collection.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Fri; Report available: 3-5 days
Reference Range
See Laboratory Report
Clinical Significance
Anti-Hu, anti-Yo, anti-CV2, anti-Ma, anti-Ta, anti-Ri, and anti-Amphiphysin antibodies are found in patients with Stiff-Person syndrome, encephalomyelitis, sensory (motor) neuropathy, cerebellar degeneration, chorea, limbic encephalitis, optic neuritis, autonomic neuropathy, brainstem encephalitis, and/or opsoclonus-myoclonus. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.